CG Oncology Inc. Common stock (CGON)
Stock · NASDAQ · Health Care
$59.87as of 10/16/2026
Price chart
Active signals
CGON Signal Track Record
How signals performed across all stocks →What CGON's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 13 | +8.2% | 62% | September 18, 2026 |
| Bollinger Band Breakdown | 10 | +4.5% | 50% | September 24, 2026 |
| Bollinger Band Breakout | 11 | -4.1% | 27% | August 10, 2026 |
| Any 20-session window (baseline) | +1.8% | 56% |
Computed by MarketWall from daily closing prices since November 7, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CGON
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 142
- Website
- www.cgoncology.com/
Fundamentals
- 1-day range
- $59.42$62
- Market cap
- $6.60B
- P/E (trailing)
- —
- P/E (forward)
- -19.81
- EPS (trailing)
- $-2.70
- Dividend yield
- —
- Beta
- 0.25
- Avg. volume
- 873.7K
How CG Oncology Inc. Common stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
CG Oncology Inc. Common stock Competitors
Chosen by industry and closest market cap.
- CGONCG Oncology Inc. Common stock$59.85▼ 3.25%Market cap $6.60BP/E —$35.8$80.97
- TWSTTwist Bioscience Corporation Common Stock$132.75▼ 8.13%Market cap $6.84BP/E —$23.3$219.71
- SRRKScholar Rock Holding Corporation Common Stock$39.9▼ 1.82%Market cap $6.31BP/E —$27.07$61.76
- IBRXImmunityBio Inc. Common Stock$9.18▼ 8.20%Market cap $7.76BP/E —$1.95$12.43
- IMVTImmunovant Inc. Common Stock$26.73▼ 2.84%Market cap $8.20BP/E —$16.6$45.42
- CRSPCRISPR Therapeutics AG Common Shares$49.25▼ 4.41%Market cap $4.99BP/E —$44.12$75.06
- PCVXVaxcyte Inc. Common Stock$63.62▼ 2.53%Market cap $8.50BP/E —$39.87$90.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CGON CG Oncology Inc. Common stock | $6.60B | — | $59.85 | ▼ 3.25% | $35.8$80.97 |
| TWST Twist Bioscience Corporation Common Stock | $6.84B | — | $132.75 | ▼ 8.13% | $23.3$219.71 |
| SRRK Scholar Rock Holding Corporation Common Stock | $6.31B | — | $39.9 | ▼ 1.82% | $27.07$61.76 |
| IBRX ImmunityBio Inc. Common Stock | $7.76B | — | $9.18 | ▼ 8.20% | $1.95$12.43 |
| IMVT Immunovant Inc. Common Stock | $8.20B | — | $26.73 | ▼ 2.84% | $16.6$45.42 |
| CRSP CRISPR Therapeutics AG Common Shares | $4.99B | — | $49.25 | ▼ 4.41% | $44.12$75.06 |
| PCVX Vaxcyte Inc. Common Stock | $8.50B | — | $63.62 | ▼ 2.53% | $39.87$90.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- SBIO: Big Pharma Needs What This Fund OwnsSeekingAlpha · 9/22/2026
- CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/14/2026
- 3 Stocks Call Traders Are Targeting TodayYahoo · 9/11/2026
Insider Activity
Insider Actions →- POST LEONARD E · September 15, 2026 · Option Exercise1.0K @ $0.6
- POST LEONARD E · September 15, 2026 · Sale1.0K @ $72.98
- POST LEONARD E · August 14, 2026 · Option Exercise1.0K @ $0.6
- POST LEONARD E · August 14, 2026 · Sale1.0K @ $74.54
- POST LEONARD E · July 15, 2026 · Option Exercise1.0K @ $0.6
- POST LEONARD E · July 15, 2026 · Sale1.0K @ $71.17
- Mulay James · July 10, 2026 · Option Exercise24.2K @ $26.63
- Mulay James · July 10, 2026 · Sale24.2K @ $75.16
- POST LEONARD E · June 24, 2026 · Option Exercise5.0K @ $0.6
- POST LEONARD E · June 24, 2026 · Sale5.0K @ $70
- POST LEONARD E · June 22, 2026 · Option Exercise5.0K @ $0.6
- POST LEONARD E · June 22, 2026 · Sale5.0K @ $65
- Mulay James · June 15, 2026 · Sale654 @ $60.12
- Mulay James · June 15, 2026 · Option Exercise1.3K @ $12.59
- Mulay James · June 15, 2026 · Option Exercise654 @ $3.72
Institutional Ownership
March 31, 2026
- Total shares held
- 88.14M
- Total value held
- $5.20B
- Institutional holders
- 232
- Unknown6.98M
- Unknown6.72M
- Unknown6.37M
- Unknown5.37M
- Unknown5.06M
- Unknown3.76M
- Unknown3.67M
- Unknown3.65M
- Unknown3.03M
- Unknown2.76M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
CG Oncology appoints Isabel Kalefonos as Chief Commercial Officer
CG Oncology announced the appointment of Isabel Kalefonos as its new chief commercial officer. The hire adds experienced biopharmaceutical leadership as the company prepares for a possible bladder cancer product launch. The addition may strengthen the commercial strategy ahead of upcoming market activities.
CG Oncology appoints Isabel Kalefonos as Chief Commercial Officer. CG Oncology announced the appointment of Isabel Kalefonos as its new chief commercial officer. The hire adds experienced biopharmaceutical leadership as the company prepares for a possible bladder cancer product launch. The addition may strengthen the commercial strategy ahead of upcoming market activities.